Exagen Inc. Reports Fourth Quarter and Full Year 2020 Results
SAN DIEGO, March 16, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year ended December 31, 2020. Recent Highlights: Generated total revenue of $42.0 million for the year ended December 31, 2020, a 4% increase over 2019.Generated total revenue of $12.7 million for the fourth quarter of 2020, a 24% increase over the fourth quarter of 2019.Generated gross margin of $8.3 million and 66% for the fourth quarter of 2020.Delivered 28,601 flagship AVISE® CTD tests, including AVISE® Lupus, in the fourth quarter 2020, and 100,450 tests for the year ended December 31, 2020.Numbe
